Payment & Shipping Terms | Supply Capacity |
Payment Terms: | T/T, WU | Production Capacity: | 1000kg/year |
Min. Order: | 1 Gram | Packing: | according to the customer's requirements |
Means of Transport: | Ocean, Air, Land | Delivery Date: | 7 days |
Regorafenib
CAS 755037-03-7
Regafinil is a small multi kinase inhibitor, its molecular structure is similar to sorafenil, the difference is only the fluorine atom on the intermediate benzene ring. It is a new molecular targeted drug developed by Bayer company. On September 27, 2012, it was approved by the US Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancer. On February 25, 2013, it was approved by the FDA for the treatment of advanced GIST patients who could not be operated and other treatment methods were invalid. Regafinil is a novel oral multi-target protein kinase inhibitor, which can block tumor cell proliferation, inhibit tumor angiogenesis and regulate tumor microenvironment, and has good antitumor activity. "Correct" study confirmed that it is a TKI with therapeutic activity for patients with metastatic colorectal cancer. Based on the data of this study, in September 2012, the U.S. FDA approved it to treat patients with MCRC who have failed to receive multi-line standard treatment. In China, a multicenter phase III clinical trial of regafinil for the treatment of Chinese patients with MCRC is under way.
We can customize according to customer's requirement
if you have any question pls mail us or call us.
